Stern Sadie sold $227K of DXCM

Dexcom's new G7 15 Day continuous glucose monitor, authorized by Health Canada, offers up to 15.5 days of wear and will be available in Canada in November. The company claims it is the longest-lasting and most accurate CGM system. Public and private reimbursement will be in place, making it accessible to eligible Canadians with diabetes. Dexcom aims to simplify glucose management with fewer sensor changes and reduced waste.

DexCom (DXCM) shares rose following the publication of positive results from its CONNECT trial in the New England Journal of Medicine, which may support Medicare coverage for its G7 insulin pump in type 2 diabetes.

Dexcom G7 CGM technology showed significant improvement in glucose control for Type 2 diabetes patients, reducing A1C levels by 1.6% on average. The study, published in NEJM, found users spent 5 more hours daily in target glucose range. Benefits were consistent across diverse participants, including those on GLP-1 medications, according to Dexcom.

DexCom (DXCM) promoted its CFO, Jereme Sylvain, to also serve as COO, expanding his role to include global operations and quality. The company's stock has seen volatility, with a 3.1% drop over the past week and a 30.2% gain year-to-date. Analysts suggest a fair value of $94.48, indicating a modest discount at the current price of $86.62.

DexCom (DXCM) has promoted former CFO Jereme Sylvain to the role of Chief Operating Officer. The announcement highlights a leadership change at the company, which may impact investor perception.

DexCom (DXCM) appointed Jereme Sylvain as COO and Glenn Boehnlein to its board, focusing on execution, supply chain, and capital allocation. The company projects $6.8B revenue and $1.5B earnings by 2029, with analysts expecting 11.2% yearly growth. Investors watch leadership changes for impact on expansion and execution.